Navigation Links
Semafore's PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma
Date:4/14/2008

SAN DIEGO, April 14 /PRNewswire/ -- Semafore Pharmaceuticals Inc. announced today on the occasion of a poster presentation at the 2008 AACR Annual Meeting that its integrin-targeted PI3 kinase inhibitor, SF1126, was shown to cause significant tumor regression in combination with rapamycin in a renal cell carcinoma mouse model. The combination of SF1126 (20 mg/kg i.v., 3x/week) with rapamycin (1.5 mg/kg i.p., 3x/week) administered simultaneously showed a 54 percent regression of the tumor volume versus starting tumor volume. This efficacy was significantly better than treatment with either agent alone or where the two agents were administered sequentially.

Angiogenesis plays a major role in the progression of renal cell carcinoma, and SF1126 was shown to dose-dependently inhibit endothelial cell proliferation in an in vitro model, while the mTOR inhibitor rapamycin (sirolimus) had no significant effect. SF1126 also showed dose-dependent cell signal (pAkt) inhibition in both renal cell carcinoma cells and endothelial cells under stimulation conditions using the growth factors IGF, VEGF and Bv8.

"There is significant biological rationale for combining targeted therapeutic agents in oncology to improve efficacy," said Dr. Dennis McKeever, Semafore's Chief Executive Officer. "The combination of SF1126, our lead product candidate, with rapamycin exhibited synergistic anticancer effects, and this increased effect was optimal when the agents were administered in combination as opposed to sequentially. SF1126 is currently in Phase I clinical trials in both solid tumors and multiple myeloma."

About SF1126

SF1126 is a small molecule conjugate containing a pan-PI3K inhibitor that selectively inhibits all PI3K class I isoforms and other key members of the PI3K superfamily, including DNA-PK and mTOR. A major factor in tumor resistance to approved chemotherapy agents is thought to be the activation of the PI3K/PTEN pathway. As a result, it is thought that inhibiting this pathway via SF1126 could cause the resetting of sensitivity to approved agents and exhibit synergistic anticancer effects.

About Semafore

Semafore is a clinical stage drug discovery and development company focused on small molecule modulators of the PI3 kinase and PTEN cell signaling pathway, a promising target pathway for multiple disorders, including the company's focus -- cancer. Semafore is one of the first biopharmaceutical companies to focus on both PI3K and PTEN and has successfully discovered and is developing a portfolio of drug candidates addressing these targets. For more information see the company's Web site at http://www.SemaforePharma.com.

Contacts:

Corporate Media & Investor

Semafore Pharmaceuticals Inc. Russo Partners LLC

Sandi Yurichuk Timothy Engel

sandi.yurichuk@semaforepharma.com timothy.engel@russopartnersllc.com

(650) 576-5769 (212) 845-4242


'/>"/>
SOURCE Semafore Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
2. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
3. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
4. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
5. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
6. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
7. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
8. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
9. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
10. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
11. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... LG Innotek hat heute die weltweit erste ... das 1,5-fache des 45-mW-Moduls der Konkurrenz. UV-C ... und 280 nm und eignet sich damit für Sterilisationsaufgaben. Es ... zerstört. Das Produkt von LG Innotek erzeugt UV-Strahlung im ... ...
(Date:2/23/2017)... Februar 2017 Im Rahmen seiner Schlüsselwachstumsstrategie ... in der südwestlichen chinesischen Provinz Guizhou, 2017 mit dem Angebot ... aktiv an der Entwicklung einer eingebetteten Hightech-Schlüsselindustrie. Foto ... Reading ... ...
(Date:2/23/2017)... 23, 2017 Obese people are ... for varicose veins in their body. The rising number ... the adoption of endovenous laser therapy for treatment of ... laser therapy market, published by Future Market Insights, ... and consequences of obesity have collectively factored the growth ...
Breaking Medicine Technology:
(Date:2/24/2017)... NJ (PRWEB) , ... February 24, 2017 , ... ... that provides business development, education, networking and recognition opportunities as well as advocacy ... Bell Works in Holmdel, NJ on February 23. The Council's Innovation Forecast ...
(Date:2/24/2017)... ... February 24, 2017 , ... With millions of Americans and ... that we all are aware of our options and are empowered with strength ... the launch of its newest edition of "Vision and Hearing" in USA Today, ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... Yisrayl Hawkins, ... focuses on Bible Prophecy concerning this present generation. Yisrayl makes an astounding statement ... current generation. He explains that the Bible details the current times so plainly ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... qualifying into the Senior International Elite division on February 12th. Ms. Esparza ... divisions at the elite qualifier competition held in Las Vegas, Nevada. Frida is ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Lymphoma ... innovative lymphoma research and serving the lymphoma community through a comprehensive series of ... Gorce Country Club in Miami Beach to host its Swirl: Miami Wine Tasting ...
Breaking Medicine News(10 mins):